in 20-to 29-year-old and 60-to 69-year-old individuals. 1, [3] [4] [5] [6] [7] IgAV is often involved with the kidneys, which is called IgAV with nephritis (IgAVN): 30%-50% of children and 45%-85% of adult cases. 1, 3 They also reported that adult patients with IgAVN have a higher rate of renal involvement and, thus, a greater risk of progression to endstage kidney disease (ESKD) than children. [6] [7] [8] [9] Clinical findings at the time of diagnosis indicated advanced age, baseline renal function, lower serum albumin levels, hypertension, and proteinuria to be risk factors for ESKD. 7, 8, [10] [11] [12] A multicenter retrospective cohort study, using the Japan Renal Biopsy Registry, demonstrated that age older than 65 years and hypoalbuminemia were the independent prognostic factors for a decline in renal function. 13 Although gastrointestinal bleeding (GIB) because of various causes, such as hemorrhagic erosions and ulcers, is common, 9, 14, 15 its impact on renal prognosis in patients with IgAVN remains uncertain. In addition, patients with IgAV often visit primary care physicians with common complaints such as palpable purpura, arthritis, and gastrointestinal symptoms, so that study on the prognosis of IgAV is relevant for general physicians. Therefore, we conducted this retrospective cohort study to investigate the effects of GIB on renal prognosis and mortality; furthermore, we examined the factors that affect the progression to ESKD in adult patients with IgAVN. patients were included in our study. This study was conducted according to the Declaration of Helsinki and was approved by the institutional review board of Teine Keijinkai Medical Center (approval no. 2018-173). The participants in this study provided their written informed consent. The findings of this study follow the checklist for STROBE, that is, Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), for observational studies. 16 We performed a chart review of patients with IgAVN using the Teine Keijinkai Renal Biopsy Registry (TK-RBR) at Teine Keijinkai Medical Center and gathered information between January 1, 2000, and December 31, 2018.
| ME THODS

| Patients
| Definitions and measurements
The main measurement of exposure in this study was GIB one month before and after the diagnosis of IgAVN, which had been defined as endoscopically proven GIB, melena, and/or hematemesis. Baseline characteristics, as well as laboratory and pathological data, were evaluated by physicians in charge of each patient in every individual case at the time of the initial evaluation. Hypertension was defined as a state in which systolic blood pressure was greater than 140 mm Hg and/or diastolic blood pressure was greater than 90 mm Hg, and antihypertensive drugs were being used as treatment before diagnosis of IgAVN. Diabetes mellitus was defined as the condition in which HbA1c was greater than 6.5% The primary outcome of interest that was measured here was the incidence of ESKD, which was indicated by an eGFR less than 15 mL/min/1.73 m 2 or the initiation of renal replacement therapy, including hemodialysis, peritoneal dialysis, or renal transplant within 5 years of diagnosis. The incidence of ESKD was ascertained from each patient's medical records prepared by the physicians in charge of them. Secondary outcomes recorded here were time to death from any cause and time to clinical remission, which was defined as the disappearance of hematuria and proteinuria. The disappearance of hematuria was defined as a condition with fewer than 5/ high-power field of erythrocytes in sediment or (−) to (±) in dipstick tests. The disappearance of proteinuria was defined by the presence of less than a total of 0.3 g/d of protein in urine samples collected over a 24-hour period or urine protein/urine creatinine ratio of less than 0.3, when recorded from spot urine or (−) to (±) dipstick tests.
The follow-up period was defined as the time from the initial diagnosis to (a) incidence of ESKD or (b) the last follow-up visit, whichever came first. Cases in which death occurred before ESKD incidence were not considered for further analysis.
| Statistical analyses
We used Student's t test or the Wilcoxon rank-sum test to compare continuous variables based on their distributions, and Fisher's exact test to compare the proportions of categorical variables between the GIB and non-GIB groups. The normality of the variance for each continuous variable was analyzed using the Shapiro-Wilk W test.
The ISKDC classification was compared between the groups using single-factor analysis of variance (ANOVA).
We used the Kaplan-Meier method to estimate incidences of ESKD, clinical remission, and death; the records thus obtained were compared by using the log-rank tests. Data were censored on December 31, 2018. Patients who were lost till the time of follow-up were removed at the date of the last contact. Patients who were alive on December 31, 2018, were considered for analysis. We used Cox proportional hazards models to assess the association of GIB and several covariates with the incidence of ESKD; the results were expressed as hazard ratios (HR) with 95% confidence intervals (CI). All the independent variables included in univariable analyses were either categorical (coded as 0/1) or quantitative. Categorical variables included hypertension, RASi, endocapillary proliferation lesions (≥25%), steroid pulse therapy, and GIB. Quantitative variables included age, gender, urinary protein levels, eGFR, and serum red blood cell counts. Multivariable Cox analyses were applied to determine the relationship between the incidence of ESKD and GIB, as well as age, gender, hypertension, and urinary protein levels.
Variables included in the multivariable Cox analysis were selected based on previous studies and the results of the univariable analysis.
The sample size calculation was based upon the primary outcome, which was estimated to be 50% 17 in the GIB group and 20% 8, 10, 11, 18 in the non-GIB group. With a significance threshold of P = .05 in statistical analyses and 80% statistical power, the total sample size was calculated to be 80 after adjusting for 5% attrition, leaving 40 individuals in each group.
We have presented data on continuous variables as means with standard deviations (SD) or medians with associated interquartile ranges, while categorical variables are presented as numbers and percentages. We used the STATA software (version 15.1; StataCorp LLC) to perform statistical analyses. All the reported P-values are two-sided. We considered a P-value less than .05 to indicate statistical significance.
| RE SULTS
| Patients
Among the 1085 eligible patients who were registered in the TK-RBR from January 1, 2000, to November 30, 2018, at the Teine Keijinkai Medical Center, 35 (3.4%) only the patients with IgAVN were included in this study. We excluded three patients who had not completed the one-month follow-up requirement and two patients who had missing data. The remaining 30 patients were included in further analyses.
| Clinicopathological characteristics and treatment modalities
Baseline clinicopathological characteristics are summarized in Table 1 . The incidence of ESKD was significantly higher in the GIB group (five events, 50%) than in the non-GIB group (one event, 5%) (logrank test, P = .003) ( Figure 1) . Additionally, the incidence of clinical remission was significantly lower in the GIB group (2 events, 20%) than in the non-GIB group (15 events, 75%) (log-rank test, P = .003) ( Figure 2) . A total of 2 (6.7%) deaths occurred, both in the GIB group as a result of hemorrhagic shock secondary to massive GIB.
| Between-group comparison of primary and secondary outcomes
However, the mortality rate was not significantly different between the two groups (log-rank test, P = .07).
| Factors affecting progression to ESKD
As per the univariable analysis with Cox proportional hazards models ( Table 3 describes multivariable analyses with Cox proportional hazards models. In Model 1, which was adjusted for age and gender, GIB remained independently associated with progression to ESKD (HR, 22; 95% CI, 1.63-296). However, GIB lost this association after further adjustment for urinary protein levels and hypertension (Models 2 and 3).
| D ISCUSS I ON
This study investigated the clinical impacts of GIB in adult patients with IgAVN and identified the factors that affect progression to ESKD. The results showed that patients who developed GIB were at a higher risk of ESKD with lower chances of clinical remission.
Although the relationship was not statistically significant, the patients with GIB tended to have more deaths than those without GIB. Although GIB is not independently associated with progression to ESKD with adjustment for covariates, our results suggest that assessment of GIB may be an effective method to identify patients with IgAVN who are at a high risk of ESKD.
The renal prognosis in adult patients with IgAVN was worse than that in children. 9 Previous studies have shown that it ranged from 9% to 27% because of substantial heterogeneity across studies, as well as limitations in study designs, patient populations, and definition of outcomes. 8, 10, 11, 18 A more recent study, using the Japan Renal Biopsy Registry, reported that the rate of decline in renal function (defined as a 50% increase in sCr from baseline or ESKD with renal replacement therapy) was 21.7% in Japanese patients with IgAVN. 13 In the present study, 20% of the patients reached ESKD in the 5-year follow-up period, comparable to results from the previous study. 18 Additionally, our results from the univariable analysis are in line with previous studies, demonstrating that urinary protein levels and hypertension are independent predictors of renal prognosis in patients with IgAVN. 10, 12, 18 We found out that patients with GIB are more likely to develop ESKD and less likely to reach clinical remission than those without GIB. This may be biologically plausible because GIB can cause anemia and subsequent hypo-oxygenation of the kidney, contributing to the development of ESKD. 19 Although GIB is one of the most acute life-threatening clinical manifestations, 9 only a few studies have reported an association between GIB and long-term progression to ESKD. A recent retrospective cohort study in France 6 reported that 43/137 (31%) patients with IgAV had GIB; however, they did not investigate the effect of GIB on the renal prognosis as we did in our study.
This study showed that the GIB group tended to have higher mortality than the non-GIB group, although the difference was not statistically significant between the groups. This may simply be because of the small sample size (type II error). Interestingly, we observed a relatively higher mortality of 2/30 (6.7%) patients than that reported in prior studies 6, 18 despite aggressive treatment with high-dose corticosteroids. The reasons remain unclear, but one possible explanation may be related to the inclusion of more severe cases in our study: The baseline sCr levels (1.21 ± 0.92 mg/ dL vs 0.91 ± 0.46 mg/dL) and the percentage of urine protein, that is, >3 g/d (32% vs 23%), were higher in our cohort than in the study performed using the Japan Renal Biopsy Registry. 13 We observed that GIB has a statistically significant association with ESKD with an adjustment for patients' age and gender; however, this result should be interpreted cautiously because it has a wide 95% confidence interval. Besides, GIB was not statistically significant after further adjustment with urinary protein levels and hypertension. Therefore, we could not conclude that GIB is an independent prognostic factor of ESKD in this study. Baseline characteristics, including age, BUN, and sCr, were not included in the multivariable analysis because they were similar in the two groups.
In addition, we did not include ISKDC classification and crescentic lesions in the Cox proportional hazards models because the association between ISKDC classification and renal prognosis has not been observed previously in adult patients with IgAVN 12,20 ; furthermore, a recent retrospective cohort study reported that the proportion of crescents is not associated with a higher risk of ESKD. 21 Most previous studies were performed on pediatric patients and have reported mixed results for the effectiveness of corticosteroids and other immunosuppressive agents, partly because of the differences in the sample populations and definitions of clinical outcomes.
While several studies have reported the efficacy of prednisolone therapy in treating renal symptoms 8, 22, 23 , a recent prospective study reported that there is no difference in the renal outcomes between the prednisolone-treated and nontreated patients. 24 Therefore, we did not conduct a comparison of therapeutic effects of different in patients with IgAVN. Finally, we provide univariable analyses of ESKD, but we were unable to perform robust multivariable analyses for the outcome because of the limited number of events. 25 Prospective enrollment and multicenter data collection from the time of diagnosis would have been ideal but are difficult to achieve with a single-center study.
In conclusion, we performed a retrospective study on a patient cohort with IgAVN to compare the outcomes between the GIB and non-GIB groups. This study indicated that GIB is associated with the incidence of ESKD, as well as clinical remission in patients with IgAVN, but it failed to be identified as an independent predictor of ESKD. Although these findings should be interpreted in the context of the small sample size, GIB may be a useful indicator for identification of patients with IgAVN at a high risk of ESKD.
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